

Patología		IFDE4	anti-TNF				anti-IL12/23	anti-IL17RA	anti-IL17A		ANTI-IL23p19		
		APR	ADA	ETA	INF	CER	UST	BRO	SEC	IXE	GUS	RIS	TIL
Psoriasis	Ensayos clínicos	1-2	13-16	31-35	51-53	64-66	77-79	91-93	98-107	135-139	155-158	167-171	180-183
	Artículos	3-4	17-20	36-40	54-56	67-68	80-82	94-95	108-116	140-143	159-162	172-174	184
APs	Ensayos clínicos	5-9	21-22	34,41-42	57	69-71	83-84	96	117-124	144-146	163-164	175-177	185-187
	Artículos	10-11	23-25	39,43	58-59	72	85-86	-	125-128	147-148	165-166	-	-
EspA axial No-Rx	Ensayos clínicos	-	26	44	60	73-74	87	97	129	149	-	-	185
	Artículos	-	27	45	61	75-76	86,88	-	-	150	-	-	-
EspA axial Rx	Ensayos clínicos	12	28-29	46-48	62	74	89-90	97	130-133	151-152	-	178	185
	Artículos	-	30	49-50	63	76	86,88	-	134	153-154	-	179	-

**Tabla suplementaria 1.** Enumeración bibliográfica de las referencias de ensayo clínicos y artículos de la tabla 5 (ver listado referencias).



1. Clinical trials.gov [Internet]. NCT01194219. Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01194219?term=NCT01194219&draw=2&rank=1>
2. Clinical trials.gov [Internet]. NCT01232283. Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (ESTEEM 2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01232283?term=NCT01232283&draw=2&rank=1>
3. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). *J Am Acad Dermatol*. 2015; 73: 37-49.
4. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). *Br J Dermatol*. 2015; 173: 1387-99.
5. Clinical trials.gov [Internet]. NCT01172938. Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE-1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01172938?term=NCT01172938&draw=2&rank=1>
6. Clinical trials.gov [Internet]. NCT01212757. PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01212757?term=NCT01212757&draw=2&rank=1>
7. Clinical trials.gov [Internet]. NCT01212770. PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE 3). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01212770?term=PALACE+3&draw=2&rank=1>

8. Clinical trials.gov [Internet]. NCT01307423. Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) (PALACE4). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01307423?term=NCT01307423&draw=2&rank=1>
9. Clinical trials.gov [Internet]. NCT03747939. Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03747939?term=NCT03747939&draw=2&rank=1>
10. Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). *Ann Rheum Dis*. 2016; 75: 1065-73.
11. Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, et al. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. *J Rheumatol*. 2016; 43: 1724-34.
12. Clinical trials.gov [Internet]. NCT01583374. Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis (POSTURE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01583374>
13. Clinical trials.gov [Internet]. NCT00237887. Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00237887?term=NCT00237887&draw=2&rank=1>
14. Clinical trials.gov [Internet]. NCT00235820. Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis (CHAMPION). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00235820?term=NCT00235820&draw=2&rank=1>
15. Clinical trials.gov [Internet]. NCT00735787. Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet. [Acceso: 12 de junio de 2020].

- Disponibile en:  
<https://clinicaltrials.gov/ct2/show/NCT00735787?term=NCT00735787&draw=2&rank=1>
16. Clinical trials.gov [Internet]. NCT02016482. A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en:  
<https://clinicaltrials.gov/ct2/show/NCT02016482?term=NCT02016482&draw=2&rank=1>
  17. Menter A, Tying SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. *J Am Acad Dermatol*. 2008; 58: 106-15.
  18. Saurat J-H, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne J-P, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). *Br J Dermatol*. 2008; 158: 558-66.
  19. Leonardi C, Langley RG, Papp K, Tying SK, Wasel N, Vender R, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. *Arch Dermatol*. 2011; 147: 429-36.
  20. Elewski BE, Baker CS, Crowley JJ, Poulin Y, Okun MM, Calimlim B, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial. *J Eur Acad Dermatol Venereol*. 2019; 33: 2168-78.
  21. Clinical trials.gov [Internet]. NCT00195689. Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis. [Acceso: 12 de junio de 2020]. Disponible en:  
<https://clinicaltrials.gov/ct2/show/NCT00195689?term=NCT00195689&draw=2&rank=1>
  22. Clinical trials.gov [Internet]. NCT00235885. Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) (STEREO). [Acceso: 12 de junio de 2020]. Disponible en:  
<https://clinicaltrials.gov/ct2/show/NCT00235885?term=NCT00235885&draw=2&rank=1>

23. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*. 2005; 52: 3279-89.
24. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). *Ann Rheum Dis*. 2009; 68: 702-9.
25. Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. *Ann Rheum Dis*. 2010; 69: 394-9.
26. Clinical trials.gov [Internet]. NCT00939003. Study of Adalimumab in Patients With Axial Spondyloarthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00939003?term=NCT00939003&draw=2&rank=1>
27. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis*. 2013; 72: 815-22.
28. Clinical trials.gov [Internet]. NCT00085644. Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis (ATLAS). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00085644?term=NCT00085644&draw=2&rank=1>
29. Clinical trials.gov [Internet]. NCT00478660. An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) (RHAPSODY). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00478660?term=NCT00478660&draw=2&rank=1>
30. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter,

- randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2006; 54: 2136-46.
31. Clinical trials.gov [Internet]. NCT00111436. Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00111436?term=NCT00111436&draw=2&rank=1>
  32. Clinical trials.gov [Internet]. NCT00111449. Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00111449?term=NCT00111449&draw=2&rank=1>
  33. Clinical trials.gov [Internet]. NCT00333034. Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00333034?term=NCT00333034&draw=2&rank=1>
  34. Clinical trials.gov [Internet]. NCT00245960. Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00245960?term=NCT00245960&draw=2&rank=1>
  35. Clinical trials.gov [Internet]. NCT01313221. Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis (REFINE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01313221?term=NCT01313221&draw=2&rank=1>
  36. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. *N Engl J Med.* 2003; 349: 2014-22.
  37. Papp KA, Tying S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. *Br J Dermatol.* 2005; 152: 1304-12.
  38. van de Kerkhof PCM, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-

- label extension. *Br J Dermatol*. 2008; 159: 1177-85.
39. Sterry W, Ortonne J-P, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. *BMJ*. 2010; 340:c147.
  40. Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, et al. A Randomized, blinded assessor study to Evaluate the efficacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). *J Eur Acad Dermatol Venereol*. 2015; 29: 361-6.
  41. Clinical trials.gov [Internet]. NCT00962741. Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis (CLIPPER). [Internet]. [Acceso: 12 de junio de 2020]. Disponible en:  
<https://clinicaltrials.gov/ct2/show/NCT00962741?term=NCT00962741&draw=2&rank=1>
  42. Clinical trials.gov [Internet]. NCT01421069. Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis (CLIPPER2). [Acceso: 12 de junio de 2020]. Disponible en:  
<https://clinicaltrials.gov/ct2/show/NCT01421069?term=NCT01421069&draw=2&rank=1>
  43. Foeldvari I, Constantin T, Vojinović J, Horneff G, Chasnyk V, Dehoorne J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. *Arthritis Res Ther*. 2019; 21: 125.
  44. Clinical trials.gov [Internet]. NCT01258738. Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray St [Acceso: 12 de junio de 2020]. Disponible en:  
<https://clinicaltrials.gov/ct2/show/NCT01258738?term=NCT01258738&draw=2&rank=1>
  45. Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. *Ann Rheum Dis*. 2016; 75:



1328-35.

46. Clinical trials.gov [Internet]. NCT00356356. 16.0040 Ankylosing Spondylitis Study. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00356356?term=NCT00356356&draw=1&rank=1>
47. Clinical trials.gov [Internet]. NCT00421980. An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00421980?term=NCT00421980&draw=2&rank=1>
48. Clinical trials.gov [Internet]. NCT00434044. Study Evaluating Etanercept in the Treatment of Subjects With Ankylosing Spondylitis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00434044?term=NCT00434044&draw=2&rank=1>
49. Davis JCJ, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. *Arthritis Rheum.* 2003; 48: 3230-6.
50. Calin A, Dijkmans BAC, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. *Ann Rheum Dis.* 2004; 63: 1594-600.
51. Clinical trials.gov [Internet]. NCT00106834. A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00106834?term=NCT00106834&draw=2&rank=1>
52. Clinical trials.gov [Internet]. NCT00106847. A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00106847?term=NCT00106847&draw=2&rank=1>
53. Clinical trials.gov [Internet]. NCT00251641. The Effects of Infliximab Versus

- Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00251641?term=NCT00251641&draw=2&rank=2>
54. Reich K, Nestle FO, Papp K, Ortonne J-P, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. *Lancet*. 2005; 366: 1367-74.
  55. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. *J Am Acad Dermatol*. 2007; 56: 31.e1-15.
  56. Barker J, Hoffmann M, Wozel G, Ortonne J-P, Zheng H, van Hoogstraten H, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). *Br J Dermatol*. 2011; 165: 1109-17.
  57. Clinical trials.gov [Internet]. NCT00051623. A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00051623?term=NCT00051623&draw=2&rank=1>
  58. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum*. 2005; 52: 1227-36.
  59. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis*. 2005; 64: 1150-7.
  60. Clinical trials.gov [Internet]. NCT00844805. Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) (INFAST). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00844805?term=NCT00844805&draw=2&rank=1>

61. Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. *Ann Rheum Dis*. 2014; 73: 101-7.
62. Clinical trials.gov [Internet]. NCT00207701. A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00207701?term=NCT00207701&draw=2&rank=1>
63. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. *Arthritis Rheum*. 2008; 59: 1270-8.
64. Clinical trials.gov [Internet]. NCT02326298. An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02326298?term=NCT02326298&draw=2&rank=1>
65. Clinical trials.gov [Internet]. NCT02326272. A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02326272?term=NCT02326272&draw=2&rank=1>
66. Clinical trials.gov [Internet]. NCT02346240. Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO). (CIMPACT). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02346240?term=NCT02346240&draw=2&rank=1>
67. Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). *J Am Acad Dermatol*. 2018; 79: 302-314.e6.
68. Lebwohl M, Blauvelt A, Paul C, Sofen H, Węglowska J, Piguet V, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a

- phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). *J Am Acad Dermatol*. 2018; 79: 266-276.e5.
69. Clinical trials.gov [Internet]. NCT01087788. Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01087788?term=NCT01087788&draw=2&rank=1>
  70. Clinical trials.gov [Internet]. NCT02775656. UCB Cimzia Pregnancy Follow-up Study. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02775656?term=NCT02775656&draw=2&rank=1>
  71. Clinical trials.gov [Internet]. NCT03357471. Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Acti [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03357471?term=NCT03357471&draw=2&rank=1>
  72. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). *Ann Rheum Dis*. 2014; 73: 48-55.
  73. Clinical trials.gov [Internet]. NCT02552212. Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02552212?term=NCT02552212&draw=2&rank=1>
  74. Clinical trials.gov [Internet]. NCT01087762. Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01087762?term=NCT01087762&draw=2&rank=1>
  75. Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, et al. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in

- Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol* (Hoboken, NJ). 2019; 71: 1101-11.
76. Sieper J, Landewé R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. *Arthritis Rheumatol* (Hoboken, NJ). 2015; 67: 668-77.
77. Clinical trials.gov [Internet]. NCT00267969. A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (PHOENIX1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00267969?term=NCT00267969&draw=2&rank=1>
78. Clinical trials.gov [Internet]. NCT00307437. A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00307437?term=NCT00307437&draw=2&rank=1>
79. Clinical trials.gov [Internet]. NCT00454584. An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT00454584?term=NCT00454584&draw=2&rank=1>
80. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*. 2008; 371: 1665-74.
81. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet*. 2008; 371: 1675-84.
82. Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med*. 2010; 362: 118-28.

83. Clinical trials.gov [Internet]. NCT01009086. A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01009086?term=NCT01009086&draw=2&rank=1>
84. Clinical trials.gov [Internet]. NCT01077362. A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01077362>
85. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet*. 2013; 382: 780-9.
86. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). *Ann Rheum Dis*. 2016; 75: 1984-8.
87. Clinical trials.gov [Internet]. NCT02407223. An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02407223?term=NCT02407223&draw=2&rank=1>
88. Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019; 71: 258-70.
89. Clinical trials.gov [Internet]. NCT02437162. A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF $\alpha$  Naive Participants With Active Radiographic Axial Spondyloarthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02437162?term=NCT02437162&draw=2&rank=1>
90. Clinical trials.gov [Internet]. NCT02438787. A Study to Evaluate the Efficacy and Safety

of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis. [Acceso: 12 de junio de 2020]. Disponible en:

<https://clinicaltrials.gov/ct2/show/NCT02438787?term=NCT02438787&draw=2&rank=1>

91. Clinical trials.gov [Internet]. NCT01708590. Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01708590?term=NCT01708590&draw=2&rank=1>
92. Clinical trials.gov [Internet]. NCT01708603. P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01708603?term=NCT01708603&draw=2&rank=1>
93. Clinical trials.gov [Internet]. Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3). [c Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01708629?term=NCT01708629&draw=2&rank=1>
94. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. *Br J Dermatol*. 2016; 175: 273-86.
95. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. *N Engl J Med*. 2015; 373: 1318-28.
96. Clinical trials.gov [Internet]. NCT02024646. Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02024646?term=NCT02024646&draw=2&rank=1>
97. Clinical trials.gov [Internet]. NCT02985983. A Study of KHK4827 in Subjects With Axial

- Spondyloarthritis (axSpA). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02985983?term=NCT02985983&draw=2&rank=1>
98. Clinical trials.gov [Internet]. NCT01365455. Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01365455?term=NCT01365455&draw=2&rank=1>
99. Clinical trials.gov [Internet]. NCT01358578. Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01358578?term=NCT01358578&draw=2&rank=1>
100. Clinical trials.gov [Internet]. NCT01555125. First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01555125?term=NCT01555125&draw=2&rank=1>
101. Clinical trials.gov [Internet]. NCT01406938. Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01406938?term=NCT01406938&draw=2&rank=1>
102. Clinical trials.gov [Internet]. NCT01636687. Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01636687?term=NCT01636687&draw=2&rank=1>
103. Clinical trials.gov [Internet]. NCT02074982. Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en:



- <https://clinicaltrials.gov/ct2/show/NCT02074982?term=NCT02074982&draw=2&rank=1>
104. Clinical trials.gov [Internet]. NCT02826603. Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis (CLARITY). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02826603?term=NCT02826603&draw=2&rank=1>
  105. Clinical trials.gov [Internet]. NCT02267135. Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis (SCALP). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02267135?term=NCT02267135&draw=2&rank=1>
  106. Clinical trials.gov [Internet]. NCT01806597. Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01806597?term=NCT01806597&draw=2&rank=1>
  107. Clinical trials.gov [Internet]. NCT01807520. Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01807520?term=NCT01807520&draw=2&rank=1>
  108. Langlely RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. *N Engl J Med*. 2014; 371: 326-38.
  109. Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). *Br J Dermatol*. 2015; 172: 484-93.
  110. Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). *J Am Acad Dermatol*. 2015; 73: 27-36.e1.

111. Paul C, Lacour J-P, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). *J Eur Acad Dermatol Venereol*. 2015; 29: 1082-90.
112. Thaçi D, Blauvelt A, Reich K, Tsai T-F, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. *J Am Acad Dermatol*. 2015; 73: 400-9.
113. Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, et al. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). *Dermatol Ther*. 2018; 8: 571-9.
114. Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. *J Am Acad Dermatol*. 2017; 77: 667-74.
115. Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. *J Am Acad Dermatol*. 2017; 76: 70-80.
116. Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. *Br J Dermatol*. 2019; 181: 954-66.
117. Clinical trials.gov [Internet]. NCT01392326. Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01392326?term=NCT01392326&draw=2&rank=1>
118. Clinical trials.gov [Internet]. NCT01752634. Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01752634?term=NCT01752634&draw=2&rank=1>

119. Clinical trials.gov [Internet]. NCT02294227. 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis (FUTURE 4). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02294227?term=NCT02294227&draw=2&rank=1>
120. Clinical trials.gov [Internet]. NCT02404350. Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02404350?term=NCT02404350&draw=2&rank=1>
121. Clinical trials.gov [Internet]. NCT02721966. Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement (MAXIMISE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02721966?term=NCT02721966&draw=2&rank=1>
122. Clinical trials.gov [Internet]. NCT02745080. Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (EXCEED 1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02745080?term=NCT02745080&draw=2&rank=1>
123. Clinical trials.gov [Internet]. NCT02771210. Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02771210?term=NCT02771210&draw=2&rank=1>
124. Clinical trials.gov [Internet]. NCT02662985. Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02662985?term=NCT02662985&draw=2&rank=1>

125. McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, et al. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. *Lancet Rheumatol.* 2020; 2:e227-35.
126. Kampylafka E, d'Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. *Arthritis Res Ther.* 2018; 20: 153.
127. Kampylafka E, Simon D, d'Oliveira I, Linz C, Lerchen V, Englbrecht M, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. *Arthritis Res Ther.* 2019; 21: 178.
128. McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. *Lancet.* 2020; 395: 1496-505.
129. Clinical trials.gov [Internet]. NCT04156620. Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT04156620?term=NCT04156620&draw=2&rank=1>
130. Clinical trials.gov [Internet]. NCT01358175. 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE 1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01358175?term=NCT01358175&draw=2&rank=1>
131. Clinical trials.gov [Internet]. NCT01649375. 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01649375?term=NCT01649375&draw=2&rank=1>
132. Clinical trials.gov [Internet]. NCT02008916. 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

- (MEASURE 3). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02008916?term=NCT02008916&draw=2&rank=1>
133. Clinical trials.gov [Internet]. NCT02159053. 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02159053?term=NCT02159053&draw=2&rank=1>
134. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *N Engl J Med*. 2015; 373: 2534-48.
135. Clinical trials.gov [Internet]. NCT01474512. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01474512?term=NCT01474512&draw=2&rank=1>
136. Clinical trials.gov [Internet]. NCT01597245. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01597245?term=NCT01597245&draw=2&rank=1>
137. Clinical trials.gov [Internet]. NCT01646177. A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01646177?term=NCT01646177&draw=2&rank=1>
138. Clinical trials.gov [Internet]. NCT02561806. A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02561806?term=NCT02561806&draw=2&rank=1>
139. Clinical trials.gov [Internet]. NCT03573323. A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-R). [Acceso: 12 de junio de 2020]. Disponible en:

- <https://clinicaltrials.gov/ct2/show/NCT03573323?term=NCT03573323&draw=2&rank=1>
140. Gordon KB, Colombel J-F, Hardin DS. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. *N Engl J Med*. 2016; 375: 2102.
  141. Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet*. 2015; 386: 541-51.
  142. Reich K, Pinter A, Lacour JP, Ferrandiz C, Micali G, French LE, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. *Br J Dermatol*. 2017; 177: 1014-23.
  143. Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. *Br J Dermatol*. 2020; 182: 1348-58.
  144. Clinical trials.gov [Internet]. NCT02584855. A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02584855?term=NCT02584855&draw=2&rank=1>
  145. Clinical trials.gov [Internet]. NCT02349295. A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT-P2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02349295?term=NCT02349295&draw=2&rank=1>
  146. Clinical trials.gov [Internet]. NCT03151551. A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H). [Acceso:12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03151551?term=NCT03151551&draw=2&rank=1>
  147. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al.

- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of . *Ann Rheum Dis.* 2017; 76: 79-87.
148. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester G-R, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. *Lancet.* 2017; 389: 2317-27.
  149. Clinical trials.gov [Internet]. NCT02757352. A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (COAST-X). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02757352?term=NCT02757352&draw=2&rank=1>
  150. Deodhar A, van der Heijde D, Gensler LS, Kim T-H, Maksymowych WP, Østergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. *Lancet.* 2020; 395: 53-64.
  151. Clinical trials.gov [Internet]. NCT02696785. A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02696785?term=NCT02696785&draw=2&rank=1>
  152. Clinical trials.gov [Internet]. NCT02696798. A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02696798?term=NCT02696798&draw=2&rank=1>
  153. van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 r. *Lancet.* 2018; 392: 2441-51.
  154. Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al.

- Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Nec. Arthritis Rheumatol. 2019; 71: 599-611.
155. Clinical trials.gov [Internet]. NCT02207231. A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02207231?term=NCT02207231&draw=2&rank=1>
  156. Clinical trials.gov [Internet]. NCT02207244. A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02207244?term=NCT02207244&draw=2&rank=1>
  157. Clinical trials.gov [Internet]. NCT02203032. A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02203032?term=NCT02203032&draw=2&rank=1>
  158. Clinical trials.gov [Internet]. NCT03090100. A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03090100?term=NCT03090100&draw=2&rank=1>
  159. Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator. *J Am Acad Dermatol*. 2017; 76: 405-17.
  160. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with



- randomized withdrawal and retreatment: Results from the phase III, double-blind, . J Am Acad Dermatol. 2017; 76: 418-31.
161. Langley RG, Tsai T-F, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018; 178: 114-23.
  162. Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394: 831-9.
  163. Clinical trials.gov [Internet]. NCT03162796. A study evaluating the efficacy and safety of guselkumab administered subcutaneously in participants with active psoriatic arthritis including those previously treated with biologic anti-tumor necrosis factor (TNF) Alpha Agent(s) (Discover-1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03162796?term=NCT03162796&draw=2&rank=1>
  164. Clinical trials.gov [Internet]. NCT03158285. A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03158285?term=NCT03158285&draw=2&rank=1>
  165. Deodhar A, Helliwell PS, Boehncke W-H, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF $\alpha$  inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395: 1115-25.
  166. Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395: 1126-36.
  167. Clinical trials.gov [Internet]. NCT02684370. BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02684370?term=NCT02684370&draw=2&rank=1>

168. Clinical trials.gov [Internet]. NCT02684357. BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02684357?term=NCT02684357&draw=2&rank=1>
169. Clinical trials.gov [Internet]. NCT02672852. BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02672852?term=NCT02672852&draw=2&rank=1>
170. Clinical trials.gov [Internet]. NCT02694523. BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02694523?term=NCT02694523&draw=2&rank=1>
171. Clinical trials.gov [Internet]. NCT03478787. Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03478787?term=NCT03478787&draw=2&rank=1>
172. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. *Lancet*. 2018; 392: 650-61.
173. R Langley, A. Blauvelt, M. Gooderham KP et al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results From the phase 3 IMMhance Trial. *J Am Acad Dermatol*. 2019; 81: AB52-.
174. Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. *Lancet*. 2019; 394: 576-86.
175. Clinical trials.gov [Internet]. NCT02719171. BI 655066/ABBV-066/Risankizumab

- Compared to Placebo in Patients With Active Psoriatic Arthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02719171?term=NCT02719171&draw=2&rank=1>
176. Clinical trials.gov [Internet]. NCT03671148. A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(ies) (KEEPSAKE2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03671148?term=NCT03671148&draw=2&rank=1>
177. Clinical trials.gov [Internet]. NCT03675308. A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03675308?term=NCT03675308&draw=2&rank=1>
178. Clinical trials.gov [Internet]. NCT02047110. BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT02047110?term=NCT02047110&draw=2&rank=1>
179. Baeten D, Østergaard M, Wei JC-C, Sieper J, Järvinen P, Tam L-S, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. *Ann Rheum Dis*. 2018; 77: 1295-302.
180. Clinical trials.gov [Internet]. NCT01729754. A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (reSURFACE 2) [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01729754?term=NCT01729754&draw=2&rank=1>

181. Clinical trials.gov [Internet]. NCT01722331. A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (reSURFACE 1) [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT01722331?term=NCT01722331&draw=2&rank=1>
182. Clinical trials.gov [Internet]. NCT03897088. Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03897088?term=NCT03897088&draw=2&rank=1>
183. Clinical trials.gov [Internet]. NCT03897075. Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03897075?term=NCT03897075&draw=2&rank=1>
184. Reich K, Papp KA, Blauvelt A, Tying SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. *Lancet*. 2017; 390: 276-88.
185. Clinical trials.gov [Internet]. NCT03552276. A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis. [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT03552276?term=NCT03552276&draw=2&rank=1>
186. Clinical trials.gov [Internet]. NCT04314544. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT04314544?term=NCT04314544&draw=2&rank=1>
187. Clinical trials.gov [Internet]. NCT04314531. Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2). [Acceso: 12 de junio de 2020]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT04314531?term=NCT04314531&draw=2&rank=1>

